Filing Flows › Ensysce Biosciences (ENSC) › Q1 2025
Ensysce Biosciences (ENSC) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 13, 2025
Ensysce Biosciences (ENSC) reported revenue of $1.3M for the first quarter 2025 (Q1 2025), +332% from a year earlier and +1% from the quarter before. Operating margin was -149.1%, net loss $1.9M (147.4% of revenue).
Ensysce Biosciences, Q1 2025: revenue $1.3M (+332% year over year), operating margin -149.1%, net loss $1.9M, operating cash flow −$1.7M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.3M | +1% | +332% |
| Operating profit | −$2.0M | — | — |
| Net earnings | −$1.9M | — | — |
| Operating cash flow | −$1.7M | — | — |
What changed
Revenue was $1.3M in Q1 2025, up 332% year over year and up 1% from the previous quarter.
Operating costs exceeded revenue by $2.0M, an operating margin of -149.1%. Total costs grew 53% against revenue growth of 332%. The fastest-growing cost line was Research & development (+142%). The quarter ended with a net loss of $1.9M, narrower than the previous quarter's $3.6M loss.
Operating cash flow was −$1.7M. Non-cash charges added back $16K of share-based compensation. Working capital and other items added $222K.
Questions
What was Ensysce Biosciences' revenue in the first quarter 2025?
Ensysce Biosciences (ENSC) reported revenue of $1.3M for the first quarter 2025 (Q1 2025), +332% from a year earlier and +1% from the quarter before.
Was Ensysce Biosciences profitable in the first quarter 2025?
Operating loss was $2.0M (-149.1% of revenue) and net loss $1.9M.